HUP0102767A2 - Glicin antagonista hatású tetrahidrokinolinszármazékok, eljárás előállításukra és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények - Google Patents

Glicin antagonista hatású tetrahidrokinolinszármazékok, eljárás előállításukra és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0102767A2
HUP0102767A2 HU0102767A HUP0102767A HUP0102767A2 HU P0102767 A2 HUP0102767 A2 HU P0102767A2 HU 0102767 A HU0102767 A HU 0102767A HU P0102767 A HUP0102767 A HU P0102767A HU P0102767 A2 HUP0102767 A2 HU P0102767A2
Authority
HU
Hungary
Prior art keywords
preparation
same
medicaments containing
tetrahydroquinoline derivatives
glycine antagonists
Prior art date
Application number
HU0102767A
Other languages
English (en)
Inventor
Romano Di Fabio
Original Assignee
Glaxo Wellcome S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812408.4A external-priority patent/GB9812408D0/en
Priority claimed from GBGB9812410.0A external-priority patent/GB9812410D0/en
Application filed by Glaxo Wellcome S.P.A. filed Critical Glaxo Wellcome S.P.A.
Publication of HUP0102767A2 publication Critical patent/HUP0102767A2/hu
Publication of HUP0102767A3 publication Critical patent/HUP0102767A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0102767A 1998-06-10 1999-06-08 Tetrahydroquinoline derivatives as glycine antagonists, process for their preparation and medicaments containing the same HUP0102767A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9812408.4A GB9812408D0 (en) 1998-06-10 1998-06-10 Heterocyclic compounds
GBGB9812410.0A GB9812410D0 (en) 1998-06-10 1998-06-10 Heterocyclic derivatives
PCT/EP1999/003936 WO1999064411A1 (en) 1998-06-10 1999-06-08 Tetrahydroquinoline derivatives as glycine antagonists

Publications (2)

Publication Number Publication Date
HUP0102767A2 true HUP0102767A2 (hu) 2001-12-28
HUP0102767A3 HUP0102767A3 (en) 2003-01-28

Family

ID=26313826

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102767A HUP0102767A3 (en) 1998-06-10 1999-06-08 Tetrahydroquinoline derivatives as glycine antagonists, process for their preparation and medicaments containing the same

Country Status (34)

Country Link
US (3) US6362199B1 (hu)
EP (1) EP1086093B1 (hu)
JP (1) JP2002517492A (hu)
KR (1) KR100586762B1 (hu)
CN (1) CN1173970C (hu)
AP (1) AP2000002008A0 (hu)
AR (1) AR018632A1 (hu)
AT (1) ATE301650T1 (hu)
AU (1) AU753867B2 (hu)
BG (1) BG105123A (hu)
BR (1) BR9911145A (hu)
CA (1) CA2334727C (hu)
CO (1) CO5080785A1 (hu)
CZ (1) CZ293605B6 (hu)
DE (1) DE69926632T2 (hu)
DK (1) DK1086093T3 (hu)
EA (1) EA003276B1 (hu)
EE (1) EE200000733A (hu)
ES (1) ES2249010T3 (hu)
HK (1) HK1034079A1 (hu)
HR (1) HRP20000845A2 (hu)
HU (1) HUP0102767A3 (hu)
ID (1) ID27845A (hu)
IL (2) IL140062A0 (hu)
IS (1) IS5746A (hu)
MY (1) MY125037A (hu)
NO (1) NO321904B1 (hu)
NZ (1) NZ508638A (hu)
OA (1) OA11564A (hu)
PE (1) PE20000724A1 (hu)
PL (1) PL197160B1 (hu)
TR (1) TR200003652T2 (hu)
TW (1) TWI229079B (hu)
WO (1) WO1999064411A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10000311A1 (de) 2000-01-05 2001-07-12 Gruenenthal Gmbh Aminomethyl-Phonyl-Cyclohexanonderivate
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137487A1 (de) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
JP2006508077A (ja) * 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
CA2598133A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2024516C1 (ru) * 1989-02-02 1994-12-15 Яманути Фармасьютикал Ко., Лтд. Способ получения производного тетрагидробензимидазола или его фармацевтически приемлемой соли
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
DK0854867T3 (da) 1995-09-29 2002-12-02 Glaxosmithkline Spa Tetrahydroquinoliner som NMDA-antagonister
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
WO1999064411A1 (en) 1999-12-16
EE200000733A (et) 2002-06-17
NO20006227L (no) 2001-02-08
ATE301650T1 (de) 2005-08-15
IS5746A (is) 2000-11-30
CN1311785A (zh) 2001-09-05
HUP0102767A3 (en) 2003-01-28
CZ293605B6 (cs) 2004-06-16
CN1173970C (zh) 2004-11-03
EA003276B1 (ru) 2003-04-24
MY125037A (en) 2006-07-31
CA2334727C (en) 2009-08-04
BG105123A (en) 2001-11-30
DE69926632D1 (de) 2005-09-15
KR20010052722A (ko) 2001-06-25
IL140062A (en) 2007-05-15
BR9911145A (pt) 2001-03-06
PL197160B1 (pl) 2008-03-31
ES2249010T3 (es) 2006-03-16
PE20000724A1 (es) 2000-08-17
NO321904B1 (no) 2006-07-17
HK1034079A1 (en) 2001-10-12
EP1086093A1 (en) 2001-03-28
US20020052391A1 (en) 2002-05-02
NZ508638A (en) 2003-08-29
DE69926632T2 (de) 2006-01-19
PL344694A1 (en) 2001-11-19
NO20006227D0 (no) 2000-12-07
OA11564A (en) 2004-05-24
DK1086093T3 (da) 2005-11-28
KR100586762B1 (ko) 2006-06-08
TWI229079B (en) 2005-03-11
US6413985B1 (en) 2002-07-02
AU753867B2 (en) 2002-10-31
CZ20004587A3 (en) 2001-05-16
TR200003652T2 (tr) 2001-04-20
AU4509299A (en) 1999-12-30
AP2000002008A0 (en) 2000-12-31
EP1086093B1 (en) 2005-08-10
ID27845A (id) 2001-04-26
US6495566B2 (en) 2002-12-17
IL140062A0 (en) 2002-02-10
HRP20000845A2 (en) 2001-10-31
US6362199B1 (en) 2002-03-26
CO5080785A1 (es) 2001-09-25
CA2334727A1 (en) 1999-12-16
AR018632A1 (es) 2001-11-28
EA200001165A1 (ru) 2001-06-25
US20020169186A1 (en) 2002-11-14
JP2002517492A (ja) 2002-06-18

Similar Documents

Publication Publication Date Title
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
IL135920A0 (en) 2-aryl -8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor
HUP0003859A3 (en) Imidazole fused heterocyclic compounds, process for their preparation, pharmaceutical compositions containing the same and their use
HUP0102084A3 (en) Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0103224A3 (en) Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
HUP0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
HUP0002718A3 (en) Piperazine derivatives, process for their preparation and medicaments containing the same
HUP0100431A3 (en) Adamantana derivatives, pharmaceutical compositions comprising them and process for preparing them
HUP0000658A3 (en) Sulphonamide derivatives, process for their preparation, and their use as medicaments
HUP9800138A3 (en) 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives, process for producing them, pharmaceutical compositions containing the same and their use
HK1042245A1 (en) Pharmaceutical moxifloxacin preparation.
IL138969A0 (en) Anthranilic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0004747A3 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation
HUP0102512A3 (en) Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
HUP0003748A3 (en) Halogen substituted tetracyclic tetrahydrofuran derivatives, process for their preparation their use and pharmaceutical compositions containing the same
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
IL113103A0 (en) Piperidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL143577A0 (en) Piperazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HK1039122A1 (zh) 取代的6-苄基-4-氧代嘧啶，其製備方法以及含該化合物的藥物組合物
HUP0104033A3 (en) 1-benzoyl-tetrahydropyridazine derivatives, process for their preparation, their use and medicaments containing the compounds
PL344984A1 (en) Artemisinin derivatives, method for the preparation thereof and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees